Trials / Completed
CompletedNCT01363700
Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
Double-masked, Comparison Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3, Confirmatory Study -
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- Santen Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 64 Years
- Healthy volunteers
- —
Summary
The purpose of the study is to demonstrate safety and efficacy of DE-114 ophthalmic solution compared to its Placebo and Olopatadine hydrochloride 0.1% ophthalmic solution in patients with allergic conjunctivitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DE-114 ophthalmic solution | |
| DRUG | Placebo ophthalmic solution | |
| DRUG | Olopatadine Hydrochloride 0.1% Ophthalmic Solution |
Timeline
- Primary completion
- 2012-06-01
- First posted
- 2011-06-01
- Last updated
- 2014-11-19
- Results posted
- 2014-11-05
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01363700. Inclusion in this directory is not an endorsement.